Amylyx Pharmaceuticals recently presented past first-in-human Phase 1 LUMINA trial data for its investigational ALS therapy AMX0114 at the 2026 ENCALS meeting in Madrid, reporting that the lowest 12.5...
Source LinkAmylyx Pharmaceuticals recently presented past first-in-human Phase 1 LUMINA trial data for its investigational ALS therapy AMX0114 at the 2026 ENCALS meeting in Madrid, reporting that the lowest 12.5...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.